Propyphenazone-Based Analogues as Prodrugs and Selective Cyclooxygenase‑2 Inhibitors

• Published in: ACS medicinal chemistry letters Vol. 5; no. 9; pp. 983 - 988
• Main Authors: Radwan, Mohamed F, Dalby, Kevin N, Kaoud, Tamer S
• Format: Journal Article
• Language: English
• Published: WASHINGTON American Chemical Society 11.09.2014; Amer Chemical Soc
• Subjects: Chemistry, Medicinal; Letter; Life Sciences & Biomedicine; Pharmacology & Pharmacy; Science & Technology; Prodrugs; cyclooxygenase-2 selective; drug design; NSAIDs; propyphenazone; GASTRIC-MUCOSAL DAMAGE; propyhenazone; RAT; NSAID; NSAIDS; DRUGS; NITRIC-OXIDE; NAPROXEN; prodrugs
• ISSN: 1948-5875; 1948-5875
• DOI: 10.1021/ml500156v

Improving the gastrointestinal safety profile of nonsteroidal anti-inflammatory drugs (NSAIDs) is an important goal. Herein, we report two strategies, using the nonacidic propyphenazone structure, with potential to overcome the side effects of NSAIDs. Propyphenazone was employed to temporarily mask the free acid group of the widely used NSAIDs ibuprofen, diclofenac, and ketoprofen to develop three mutual prodrugs hypothesized to have minimal GI irritation. The three prodrugs exhibit in vivo anti-inflammatory and analgesic activities with improved potency over each parent drug when compared to a nonhydrolyzable control betahistine–propyphenazone (BET–MP). Additionally, ANT–MP formed by the irreversible coupling of propyphenazone and 4-aminoantipyrine, displayed exceptional COXII selectivity (COXII IC50 of 0.97 ± 0.04 μM, compared to no observed inhibition of COXI at 160 μM). Inhibition of COXII suppresses inflammatory diseases without affecting COXI-mediated GI tract events. ANT–MP exhibited maximal analgesic effect when tested in vivo in an abdominal writhing assay (100% protection) and its anti-inflammatory activity showed a peak at 2 h in a carrageenan-induced paw edema model. Its unique selectivity toward the COXII enzyme was investigated using molecular modeling techniques.